Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).

Détails

ID Serval
serval:BIB_C7AD177ACA8A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).
Périodique
Journal of thoracic oncology
Auteur(s)
Früh M., Betticher D.C., Stupp R., Xyrafas A., Peters S., Ris H.B., Mirimanoff R.O., Ochsenbein A.F., Schmid R., Matzinger O., Stahel R.A., Weder W., Guckenberger M., Rothschild S.I., Lardinois D., Mach N., Mark M., Gautschi O., Thierstein S., Biaggi Rudolf C., Pless M.
Collaborateur(s)
Swiss Group for Clinical Cancer Research (SAKK)
ISSN
1556-1380 (Electronic)
ISSN-L
1556-0864
Statut éditorial
Publié
Date de publication
01/2019
Peer-reviewed
Oui
Volume
14
Numéro
1
Pages
115-123
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Long-term data on outcomes of operable stage III NSCLC are scarce.
Individual patient data from 368 patients enrolled in one phase III and two phase II trials were pooled and outcomes after applying the eighth (denoted with an asterisk [*]) versus the sixth TNM staging edition were compared. Patients were treated with either preoperative radiotherapy following 3 cycles of induction chemotherapy (trimodal) or neoadjuvant chemotherapy alone (bimodal).
With the sixth version, the 5- and 10-year survival rates were 38% and 28% for stage IIIA, respectively, and 36% and 24% for stage IIIB, respectively. Factors associated with improved 5-year overall survival were younger age, R0 resection, and pathologic complete remission (pCR) (p = 0.043, p < 0.001 and p = 0.009). With the eighth TNM staging version, 162 patients were moved from stage IIIA to IIIB*. The 5- and 10-year survival rates were 41% and 29% for stage IIIA*, respectively, and 35% and 27% for stage IIIB* patients, respectively. There was no difference in the bi- versus trimodal group with regard to median overall survival (28 months [95% confidence interval (CI): 21-39 months] and 37 months [95% CI: 24-51 months], p = 0.9) and event-free survival (12 months [95% CI: 9-15 months] versus 13 months [95% CI: 10-22 months], p = 0.71).
We showed favorable 10-year survival rates of 29% and 27% in stage IIIA* and IIIB*, respectively. Younger age, R0 resection, and pathologic complete response were associated with improved long-term survival. Outcomes using the sixth versus eighth edition of the TNM classification were similar in operable stage III NSCLC.
Mots-clé
Non-Small Cell Lung Cancer, long term survival, preoperative radiotherapy, stage III, Long-term survival, NSCLC, Preoperative radiotherapy, Stage III
Pubmed
Web of science
Création de la notice
16/10/2018 11:47
Dernière modification de la notice
20/08/2019 15:43
Données d'usage